Judges in England and Wales will be able to use the AI chatbot to help write their legal rulings, the Telegraph reports. This is despite ChatGPT being prone to making up bogus cases, and the tool even admitting that it'can make mistakes' on its landing page. ChatGPT, already described by one British judge as'jolly useful', is increasingly infiltrating the legal industry, leading to concern among some experts. The Judicial Office's new official guidance, issued to thousands of judges, points out that AI can be used for summarising large amounts of text or in administrative tasks. These qualify as basic work tasks, but more salient parts of the process – such as conducting legal research or undertaking legal analysis – must not be offloaded to chatbots, the guidance claims.

The deal is the latest in a stampede as tech companies seek to deploy "generative AI tech" into their products. Microsoft announced a multibillion dollar deal with OpenAI in January into use its tech to answer questions directly in its Bing search engine, while Google has said its bot, called Bard, will be available to the public soon, too. Proponents of the tech say the chatbots will revolutionize how people interact with computers and software, while skeptics point out that the bots make glaring mistakes and question whether the big companies are simply piling onto a trend to keep up their reputations for being innovative.

The days of the blockbuster drug might not be over, but they are dwindling. As markets become more crowded, pharmaceutical companies are focusing their drug development strategies on specialized populations, such as individuals with rare diseases or those with genetic subsets of chronic conditions like cancer and diabetes and cardiovascular diseases. Identifying a specific subgroup of patients from a niche population poses challenges for many companies. The integration of artificial intelligence (AI) and machine learning (ML) in a drug development and launch playbook offers new possibilities to find the right subpopulation(s) for product targeting as a way to ensure a successful launch. With the growth of big data and exponential advancements in technology, we are seeing more opportunities to apply artificial intelligence and machine learning in decision-making for drug development.